Skip to main content

Table 1 (abstract A24). Characteristics of Children with Juvenile Idiopathic Arthritis and Uveitis

From: Proceedings of the 2019 Childhood Arthritis and Rheumatology Research Alliance (CARRA) Annual Scientific Meeting

N (%), unless indicated Overall JIAa alone (n = 22) JIA-Ub (n = 22) Other Uc (n = 18)
Characteristics     
Demographics     
Age, Mean (SD)d 13.0 (3.3) 12.9 (2.8) 12.6 (3.4) 13.5 (3.9)
Gender, Male 14 (22.6) 2 (9.1) 4 (18.2) 8 (44.4)
Race
 White 53 (85.5) 21 (95.5) 20 (90.9) 12 (66.7)
 African American 5 (8.1) 1 (4.5) 1 (4.5) 3 (16.7)
 American Indian/Alaskan Native 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
 Asian 1 (1.6) 0 (0.0) 1 (4.5) 0 (0.0)
 Multi-racial 1 (1.6) 0 (0.0) 0 (0.0) 1 (5.6)
 Unknown/Declined 2 (3.2) 0 (0.0) 0 (0.0) 2 (11.1)
Ethnicity, Hispanic 1 (1.6) 0 (0.0) 1 (4.7) 0 (0.0)
JIA Characteristics
 Age at Diagnosis, Mean (SD) 6.3 (4.6) 7.7 (4.3) 4.9 (4.2)  
 Duration of Disease, years, Mean (SD) 6.5 (4.3) 5.2 (3.7) 7.7 (4.7)  
 JIA Subtype
  Oligoarticular Persistent 14 (31.8) 10 (45.5) 4 (18.2)  
  Oligoarticular Extended 9 (20.5) 3 (13.6) 6 (27.3)  
  Polyarticular RF(-) 17 (38.6) 9 (40.9) 8 (36.4)  
Uveitis Characteristics
 Age at Diagnosis, Mean (SD) 8.4 (4.5)   6.1 (4.0) 11.4 (3.0)
 Duration of Disease, years, Mean (SD) 4.8 (4.3)   6.4 (4.7) 2.8 (2.8)
 Bilateral Disease    17 (77.2) 12 (66.7)
 Anterior Chamber Cells >0.5+    1 (4.6) 2 (11.1)
 Visual Acuity 20/50 or worse    0 (0.0) 0 (0.0)
 Location     
  Anterior    22 (100.0) 13 (72.2)
  Intermediate    1 (4.5) 3 (1.7)
  Posterior    0 (0.0) 1 (5.5)
  Panuveitis    0 (0.0) 2 (11.1)
Ocular Complications, ever
 Glaucoma or Glaucoma Suspect 21 (33.9)   11 (50.0) 10 (55.6)
 Cataracts 16 (25.8)   10 (45.5) 6 (33.3)
 Synechiae 11 (17.7)   8 (36.4) 3 (16.7)
 Band Keratopathy 4 (6.5)   1 (4.5) 3 (16.7)
 Amblyopia 3 (4.8)   2 (9.1) 1 (5.6)
 Cystoid Macular Edema 1 (1.6)   1 (4.5) 0 (0.0)
 Othere 1 (1.6)   0 (0.0) 1 (5.6)
Treatment, at time of visit
 Steroid drops 24 (38.7)   11 (50.0) 13 (72.2)
 Dilating drops 2 (3.2)   2 (9.1) 0 (0.0)
 IOP-lowering dropsf 5 (8.1)   1 (4.5) 4 (22.2)
 Methotrexate oral 12 (19.4) 5 (22.7) 5 (22.7) 2 (11.1)
 Methotrexate SQ 10 (16.1) 3 (13.6) 4 (18.2) 3 (16.7)
 Mycophenolate 2 (3.2) 0 (0.0) 1 (4.5) 1 (5.6)
 Etanercept 4 (6.5) 4 (18.2) 0 (0.0) 0 (0.0)
 Infliximab 12 (19.4) 1 (4.5) 6 (27.3) 5 (27.8)
 Adalimumab 9 (14.5) 2 (9.1) 6 (27.3) 1 (5.6)
 Abatacept 1 (1.6) 0 (0.0) 1 (4.5) 0 (0.0)
 Tocilizumab 7 (11.3) 3 (13.6) 4 (18.2) 0 (0.0)
  1. aJIA: juvenile idiopathic arthritis; bJIA-U: JIA-associated uveitis; cOther U: all other uveitis not associated with JIA; d SD: standard deviation; eOther complications include: vitreous hemorrhage, optic disc edema, aphakia, choroidal neovascular membranes, choriorential scare, retinal neovascularization, retinal detachment, keratic precipitates, peri retinal fibrosis, floaters, blindness, ocular hypertension; fIOP: Intraocular pressure